Modifications to the EV surface, such as the addition of specific ligands or antibodies, can help direct these vesicles to target tissues or organs more effectively, such as the RVG peptide, that drives EVs to CNS, or antibodies like anti-EGFR, which can target drugs to cancer cells [59,63,64]. This evidence concerns the gene EGFR and cancer.